Let's Talk Alzheimer's

A new generation of Alzheimer’s therapies is tackling one of medicine’s toughest challenges: delivering drugs to the brain. Renowned Alzheimer’s researcher Dr. Gil Rabinovici explores trontinemab, an investigational anti-amyloid therapy being studied for early Alzheimer’s disease that uses innovative Brainshuttle™ technology to enhance drug delivery across the blood-brain barrier. He also shares insights from the TRONTIER 1 and 2 clinical trials, the TRAVELLER pre-screening study, and the ambiti

What if a noninvasive technology using sound waves could help unlock new possibilities for Alzheimer’s research and care? Dr. Ali R. Rezai, a leader in neuroscience and neuromodulation, explains how focused ultrasound is being used to temporarily open the blood-brain barrier, enhance delivery of anti-amyloid antibodies, enable brain biopsies for biomarker research, and improve brain function through neuromodulation. For a deeper dive into this exciting technology, watch our full conversation wit

Up to 45% of dementia cases may be preventable or delayed by addressing modifiable risk factors, recent research shows. Join Dr. Zaldy Tan as he discusses the latest evidence on reducing dementia risk, including insights from an ongoing longitudinal study examining how lifestyle interventions affect brain structure, blood-based biomarkers, and cognitive performance. Learn what the newest research reveals about protecting brain health and promoting healthy aging. For a deeper dive into evidence-b

Can brain tissue be regenerated? We spoke with Roberta Diaz Brinton, PhD, director of the Center for Innovation in Brain Science at the University of Arizona, about the ReGenBRAIN clinical trial. This Phase 2 study is testing whether the drug allopregnanolone (“Allo”) can help repair brain damage and improve thinking in people with mild Alzheimer’s who carry the APOE ε4 genetic risk factor. Dr. Brinton explains how the trial works, who can enroll, and why this approach holds promise. For a deepe

Lewy body dementia is a form of dementia caused by abnormal protein deposits in the brain known as "Lewy bodies,” with symptoms that can resemble those of Parkinson's disease. Leading neurologist Dr. James E. Galvin explains how to identify early warning signs, distinguish Lewy body dementia from Alzheimer’s disease, and explore current and emerging treatment options. He’ll also discuss mixed dementias, when a person has more than one type of dementia. For a deeper dive into vascular dementia, w

Agitation is one of the most common and challenging symptoms of Alzheimer’s disease, often causing distress for both individuals living with dementia and their caregivers. Dr. Brent Forester explains what causes agitation, how it may appear in different forms, and the latest approaches for managing symptoms—including non-drug strategies and newly approved treatments. For a deeper dive into vascular dementia, watch our full conversation with Dr. Forester, part of the Zoom In on Dementia and Alzhe